Prescient Therapeutics Ltd
ASX:PTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Prescient Therapeutics Ltd
Accounts Receivables
Prescient Therapeutics Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prescient Therapeutics Ltd
ASX:PTX
|
Accounts Receivables
AU$196.1k
|
CAGR 3-Years
-1%
|
CAGR 5-Years
28%
|
CAGR 10-Years
17%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Accounts Receivables
$42.9m
|
CAGR 3-Years
178%
|
CAGR 5-Years
81%
|
CAGR 10-Years
71%
|
|
|
CSL Ltd
ASX:CSL
|
Accounts Receivables
$4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Accounts Receivables
AU$129.2m
|
CAGR 3-Years
49%
|
CAGR 5-Years
281%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Accounts Receivables
AU$32.6m
|
CAGR 3-Years
55%
|
CAGR 5-Years
336%
|
CAGR 10-Years
110%
|
|
Prescient Therapeutics Ltd
Glance View
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Its Phase 1b clinical candidate PTX-100 is a drug that blocks the cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). PTX-200, a Phase 1b/2a clinical candidate is a PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Its OmniCAR, is an immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product is for the treatment of Acute Myeloid Leukemia (AML), Her2+ solid tumors, including breast, ovarian and gastric cancers and glioblastoma multiforme (GBM).
See Also
What is Prescient Therapeutics Ltd's Accounts Receivables?
Accounts Receivables
196.1k
AUD
Based on the financial report for Dec 31, 2025, Prescient Therapeutics Ltd's Accounts Receivables amounts to 196.1k AUD.
What is Prescient Therapeutics Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
17%
Over the last year, the Accounts Receivables growth was -13%. The average annual Accounts Receivables growth rates for Prescient Therapeutics Ltd have been -1% over the past three years , 28% over the past five years , and 17% over the past ten years .
